Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03332589
Title E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Spirita Oncology, LLC
Indications

melanoma

Therapies

Dabrafenib + E6201

E6201

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST